{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:13:44Z","timestamp":1794608024271,"version":"4.9.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors may improve treatment outcomes and individualized therapy in patients with cancer. Compared with plasma, the standard TDM matrix, dried blood microsampling is associated with several advantages, including the collection of samples by the patients themselves in their home setting. This study aimed to compare dasatinib and imatinib concentrations in different blood-based matrices and to determine whether dried capillary blood collected via volumetric absorptive microsampling (VAMS) could be used as an alternative to perform TDM in patients with chronic myeloid leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In addition to venous liquid whole blood, plasma, and VAMS samples (referred to as venous VAMS) prepared thereof, also fingerprick capillary VAMS samples were collected from patients receiving dasatinib or imatinib treatment by skilled personnel in a controlled environment. All samples were analyzed using validated liquid chromatography tandem mass spectrometry methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-three patients were included in the study: 33 were treated with dasatinib and 20 with imatinib. Although a bias between dasatinib and imatinib venous VAMS and liquid blood concentrations was observed, 94% and 95% of the samples, respectively, fulfilled the 20% difference acceptance criterion. Capillary and venous concentrations were interchangeable and independent of the collection time. Using venous blood-to-plasma ratios from a prior proof-of-concept study, the VAMS results for imatinib, but not dasatinib, could reliably be converted into plasma concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Through a clinical validation study, the authors demonstrated that VAMS is a viable alternative for imatinib monitoring in patients with chronic myeloid leukemia. For dasatinib, VAMS-based analysis may still allow for longitudinal follow-up (ie, provide insight into fluctuations in patients). As a next step, capillary microsampling can be integrated into the home sampling context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001387","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T13:00:09Z","timestamp":1758200409000},"page":"740-746","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Toward Clinical Implementation of a Volumetric Absorptive Microsampling\u2013Based Method for Dasatinib and Imatinib Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"47","author":[{"given":"Nick","family":"Verougstraete","sequence":"first","affiliation":[{"name":"Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium;"},{"name":"Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominiek","family":"Mazure","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe P.","family":"Stove","sequence":"additional","affiliation":[{"name":"Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FTD.0000000000000699","article-title":"Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: a critical review","volume":"42","author":"Cardoso","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"821807","DOI":"10.3389\/fonc.2022.821807","article-title":"Therapeutic drug monitoring of tyrosine kinase inhibitors using dried blood microsamples","volume":"12","author":"Verougstraete","year":"2022","journal-title":"Front Oncol"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"e70056","DOI":"10.1002\/bmc.70056","article-title":"Advancing therapeutic drug monitoring for oral targeted anticancer drugs: from hospital-based towards home-sampling","volume":"39","author":"Meertens","year":"2025","journal-title":"Biomed Chromatogr"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.aca.2015.04.056","article-title":"Does volumetric absorptive microsampling eliminate the hematocrit bias for caffeine and paraxanthine in dried blood samples? A comparative study","volume":"881","author":"De Kesel","year":"2015","journal-title":"Anal Chim Acta"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11095-021-03036-6","article-title":"Dried blood spot technique applied in therapeutic drug monitoring of anticancer drugs: a review on conversion methods to correlate plasma and dried blood spot concentrations","volume":"38","author":"Iacuzzi","year":"2021","journal-title":"Pharm Res"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"122140","DOI":"10.1016\/j.talanta.2021.122140","article-title":"Quantification of eight hematological tyrosine kinase inhibitors in both plasma and whole blood by a validated LC-MS\/MS method","volume":"226","author":"Verougstraete","year":"2021","journal-title":"Talanta"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"114418","DOI":"10.1016\/j.jpba.2021.114418","article-title":"Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors","volume":"207","author":"Verougstraete","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/FTD.0000000000000997","article-title":"Development and validation of a simple method for simultaneously measuring the concentrations of BCR-ABL and bruton tyrosine kinase inhibitors in dried blood spot (DBS): a pilot study to obtain candidate conversion equations for predicting plasma concentration based on DBS concentration","volume":"44","author":"Mukai","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4155\/bio.15.101","article-title":"DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application","volume":"7","author":"Antunes","year":"2015","journal-title":"Bioanalysis"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"124526","DOI":"10.1016\/j.jchromb.2025.124526","article-title":"Imatinib and norimatinib therapeutic monitoring using dried blood spots: analytical and clinical validation, and performance comparison of volumetric collection devices","volume":"1255","author":"Orleni","year":"2025","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R15-20251107","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000001315","article-title":"Clinical application of volumetric absorptive microsampling for therapeutic drug monitoring of oral targeted anticancer drugs","author":"Meertens","year":"2025","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:39Z","timestamp":1762542039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001387","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"2025-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}